Lyell Immunopharma Inc., a clinical-stage company focused on CAR T-cell therapies, has announced new management appointments to strengthen its clinical and commercial capabilities. Mark J. Bachleda, PharmD, MBA, has been appointed as an independent member of the Board of Directors. Additionally, David Shook, MD, has been named Chief Medical Officer, Mark Meltz, JD, as General Counsel and Corporate Secretary, and Jarrad Aguirre, MD, MBA, as Senior Vice-President of Medical Affairs. These changes come as Lyell advances its programs for LYL314, targeting aggressive large B-cell lymphoma.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。